SCYNEXIS Inc ( (SCYX) ) has released its Q4 earnings. Here is a breakdown of the information SCYNEXIS Inc presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
SCYNEXIS, Inc. is a biotechnology company focused on developing innovative antifungal medications to combat drug-resistant infections, with a proprietary platform known as ‘fungerps.’
In its 2024 financial report, SCYNEXIS highlighted the initiation of a Phase 1 trial for SCY-247, a second-generation antifungal, and ongoing efforts to restart the Phase 3 MARIO study for invasive candidiasis, pending FDA approval.
Key financial metrics for 2024 included a decrease in research and development expenses to $26.4 million and a reduction in SG&A expenses to $14.5 million. The company reported a net loss of $21.3 million, contrasting with a net income of $67.0 million in 2023, primarily due to lower revenue from license agreements.
Looking ahead, SCYNEXIS anticipates releasing Phase 1 trial data for SCY-247 in the third quarter of 2025 and expects to have sufficient cash reserves to support operations into the third quarter of 2026, reflecting a cautious yet optimistic outlook for its ongoing projects.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue